Tirzepatide + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Steatohepatitis
Conditions
Nonalcoholic Steatohepatitis
Trial Timeline
Nov 19, 2019 → Jan 10, 2024
NCT ID
NCT04166773About Tirzepatide + Placebo
Tirzepatide + Placebo is a phase 2 stage product being developed by Eli Lilly for Nonalcoholic Steatohepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT04166773. Target conditions include Nonalcoholic Steatohepatitis.
What happened to similar drugs?
0 of 6 similar drugs in Nonalcoholic Steatohepatitis were approved
Approved (0) Terminated (3) Active (3)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06962280 | Phase 3 | Active |
| NCT06914895 | Phase 3 | Active |
| NCT06191848 | Approved | Recruiting |
| NCT06439277 | Phase 3 | Recruiting |
| NCT05708859 | Approved | Recruiting |
| NCT06075667 | Phase 3 | Active |
| NCT06037252 | Phase 2 | Active |
| NCT06047548 | Phase 3 | Active |
| NCT05963022 | Phase 3 | Completed |
| NCT05536804 | Phase 2 | Active |
| NCT05696847 | Phase 1 | Completed |
| NCT05691712 | Phase 3 | Completed |
| NCT05556512 | Phase 3 | Active |
| NCT05412004 | Phase 3 | Completed |
| NCT05024032 | Phase 3 | Completed |
| NCT04235959 | Phase 1 | Completed |
| NCT04081337 | Phase 1 | Completed |
| NCT04050553 | Phase 1 | Completed |
| NCT04184622 | Phase 3 | Completed |
| NCT04166773 | Phase 2 | Completed |
Competing Products
20 competing products in Nonalcoholic Steatohepatitis